While the number of influenza vaccines available on the market is expected to stay high, health authorities struggle with prioritizing the introduction of new vaccines in view of real-life budgetary limitations in their regions.

We developed a methodology for assessing which influenza vaccines should be introduced and in what chronological order (i.e., vaccine ranking) to achieve the greatest possible benefit while still complying with the constraints of a multi-year financial plan.

This optimization method makes a justifiable economic argument by comparing the results generated by this model with those generated from a process where no programmed vaccine selection was made (i.e., an “uninformed” selection process).

We applied this model to the USA setting and explain in detail the model working and its relevance.